Gamma-delta hepatosplenic T-cell lymphoma. Description of a case with immunophenotypic and molecular follow-up successfully treated with chemotherapy alone.

Abstract

This study hereby reports the case of a 19-year old boy with a gamma-delta hepatosplenic T-cell lymphoma (HSTCL). Initial therapy consisted of four cycles of the IEV (Ifosphamide, Epirubicin and Etoposide) scheme. Further treatment strategy was then adapted according to minimal residual disease monitoring by immunophenotypic and T-cell receptor gamma chain gene evaluation. The patient remains in complete clinical, immunological and molecular remission and in good clinical conditions 48 months after diagnosis and 40 months after stopping therapy.

• Authors: Maria Luisa Moleti, Anna Maria Testi, Fiorina Giona, Angela Amendola, Giovanna Palumbo, Stefania Uccini, Irene Della Starza, Maria Stefania de Propris, Anna Guarini, Robin Foà
• Journal: Leukemia & lymphoma (Leuk Lymphoma) Vol. 47 Issue 2 Pg. 333-6 (Feb 2006) ISSN: 1042-8194 [Print] United States
• PMID: 16321867 (Publication Type: Case Reports, Journal Article)

Chemical References

• Receptors, Antigen, T-Cell, gamma-delta

Topics

• Adult
• Antineoplastic Combined Chemotherapy Protocols (therapeutic use)
• Flow Cytometry
• Follow-Up Studies
• Hepatomegaly (etiology)
• Humans
• Immunophenotyping
• Lymphoma, T-Cell (diagnosis, drug therapy, immunology)
• Male
• Neoplasm, Residual
• Receptors, Antigen, T-Cell, gamma-delta (biosynthesis)
• Remission Induction
• Sensitivity and Specificity
• Splenomegaly (etiology)
• Treatment Outcome